FindTrial
Sign In

Usefulness of AFP, PIVKA - II and ASAP score in diagnosis of Hepatocellular Carcinoma and their correlation with disease severity.

Diagnostic Utility of AFP, PIVKA-II, and ASAP Score in Hepatocellular Carcinoma (HCC): Correlation with Histopathological and Radiological Tumor Grading - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/07/090763
Enrollment
90
Registered
2025-07-11
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C220- Liver cell carcinoma

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

Medanta Medicity Gurugram
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults more than 18 years Patients with newly diagnosed radiologically or histologically confirmed HCC. Patients in which histopathological tumor grading has been done as per the WHO Grading system for Hepatocellular Carcinoma, radiological grading done as per on Li-RADS and severity (tumor staging/extent of disease) determined as per Barcelona Clinic Liver Cancer (BCLC) Staging.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
-Primary Objective To determine the Diagnostic value of AFP, PIVKA II, and combined ASAP score in diagnosis of Hepatocellular Carcinoma. Timepoint: At end of the study, 12 months.—

Secondary

MeasureTime frame
-Secondary Objective Correlation of AFP levels, PIVKA-II levels, & combined ASAP score to histopathological, radiological, & clinical tumor grading.Timepoint: At end of study 12 months.—

Countries

India

Contacts

Public ContactDr Ravi Singhal

Medanta Medicity Gurugram

anuj.parkash@medanta.org9643001625

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026